Calcium channel blockers: indications and limitations 1. Clinical pharmacology and use as antiarrhythmic agents.
In the atmosphere of euphoria that often surrounds introduction in the new drugs, indications may be exaggerated and limitations downplayed. This two-part article carefully assesses the advantages and disadvantages of the new calcium channel blocking drugs. In the various indications for which their use has been approved and looks into possible future applications.
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001682:Biological Availability; D002118:Calcium / Q000502:physiology; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004110:Diltiazem / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006327:Heart Block / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D009543:Nifedipine / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine; D002118:Calcium